AIDX (20/20 Biolabs) Short-Term Debt: $0.31 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AIDX 20/20 Biolabs Inc AIDX
6 GF Score
Price $0.42
! 1 Warning Sign
View Full Analysis

What is 20/20 Biolabs Short-Term Debt?

20/20 Biolabs AIDX -0.23% 6 Short-Term Debt is $0.31 Mil as of Mar. 2026. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

20/20 Biolabs's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.31 Mil.

20/20 Biolabs's quarterly Short-Term Debt increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.08 Mil) and increased from Dec. 2025 ($0.08 Mil) to Mar. 2026 ($0.31 Mil).

20/20 Biolabs's annual Short-Term Debt stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.08 Mil).

20/20 Biolabs Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

20/20 Biolabs Short-Term Debt Related Terms

20/20 Biolabs Short-Term Debt Historical Data

* Premium members only.

The historical data trend for 20/20 Biolabs's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

20/20 Biolabs Short-Term Debt Chart

20/20 Biolabs Annual Data
Trend Dec23 Dec24 Dec25
Short-Term Debt
0.00 0.00 0.08

20/20 Biolabs Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.08 0.31
AIDX
6GF Score
20/20 Biolabs Inc AIDX
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.31 Mil mean?
20/20 Biolabs (AIDX) has a Short-Term Debt of $0.31 Mil as of Mar. 2026.
Is 20/20 Biolabs' Short-Term Debt too high?
20/20 Biolabs' current Short-Term Debt is $0.31 Mil. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' Short-Term Debt compare to STME and TRIB?
20/20 Biolabs' Short-Term Debt of $0.31 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. 20/20 Biolabs's current Short-Term Debt is $0.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current Short-Term Debt of $0.31 Mil. The current Short-Term Debt is $0.31 Mil. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current Short-Term Debt is $0.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

20/20 Biolabs Business Description

Address 15810 Gaither Road, Suite 235, Gaithersburg, MD, USA, 20877
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score

Get the complete analysis for AIDX

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price